FDA panel recommends DNA test as first line cervical cancer screening testBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2164 (Published 17 March 2014) Cite this as: BMJ 2014;348:g2164
- Michael McCarthy
A US Food and Drug Administration advisory panel has voted unanimously (13-0) to recommend that a DNA test for the human papillomavirus (HPV) be approved as a first line cervical cancer screening test, challenging the role of the cytological smear test.
The FDA is not bound by its advisory panels’ recommendations, but it usually heeds their advice.
The Cobas HPV test, made by Roche Molecular Systems, uses DNA amplification with polymerase chain reaction and nucleic acid hybridization to provide specific genotype information for the highest …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial